SCIENTIFIC MARKETING PRESENTATION · ENGLISH
PuriActives®MEVAL 100L
Mevalonolactone 100LHigh-purity mevalonolactone enabled by synthetic biology
(R)-mevalonolactone · C6H10O3 · MW 130.14
A foundational metabolite of the mevalonate pathway, brought into modern skin and hair science through precision biotechnology.
| High purityDefined, controlled composition | High activityMevalonate pathway biology |
| Clean productionControlled biosynthesis | Green biotechnologyResource-efficient platform |
OPENING PERSPECTIVE
A new generation of metabolic actives is reshaping skin science
Cosmetic science is moving beyond conventional antioxidant and moisturizing concepts toward support for more fundamental biological processes: cellular energy, lipid synthesis, metabolic signaling, epidermal renewal, and barrier homeostasis.
Healthy skin depends not only on structural components, but also on the metabolic pathways that continuously build and maintain them.
Five core processes in metabolic skin scienceCellular energyLipid synthesisMetabolic signalingEpidermal renewalBarrier homeostasis
NARRATIVE MAP
Five questions, one complete storyline
| 01 | Why is the mevalonate pathway essential to skin and hair biology? |
| 02 | Why is mevalonolactone scientifically compelling as a cosmetic active? |
| 03 | What evidence supports its biological relevance—from cells to human skin? |
| 04 | Why do high purity and synthetic-biology production matter to formulators? |
| 05 | What new product concepts can be built with PuriActives® MEVAL 100L? |
Storyline: Biology (the mevalonate pathway in skin and hair) → Evidence (cells, 3D epidermis, human studies) → Scalp and hair → Platform (synthetic biology and purity) → Applications.
CHAPTER 01 · BIOLOGY
The mevalonate pathway: a central metabolic hub linking lipid synthesis, cellular signaling, and tissue homeostasis
It operates in both the epidermis and the hair follicle.
1.1 Skin care is shifting from surface correction to metabolic support
Healthy skin depends not only on structural components, but also on the metabolic pathways that continuously build and maintain them.
| Traditional model | Metabolic model |
|---|---|
| Supply finished materials from the outside:· Occlusive and humectant moisturization· Topical lipid supplementation· Antioxidant quenching· Surface exfoliationThese benefits are real, but often symptomatic and temporary. | Support the pathways that generate skin lipids and signals:· De novo lipid biosynthesis· Lipid transport and secretion· Metabolic signaling (PPAR, ABCA12)· Epidermal renewal capacityThis approach targets the underlying mechanism of barrier homeostasis. |
Where MEVAL 100L fits: mevalonolactone supplies substrate to the mevalonate pathway—the metabolic route through which every epidermal cell synthesizes cholesterol and isoprenoids.
1.2 Mevalonolactone: a stable, ready-to-use form of a foundational metabolite
ode=”block” data-draft-type=”table” data-size=”normal” data-row-style=”normal”>
| (R)-mevalonolactoneLactone form | (R)-mevalonateOpen-chain form |
aft-node=”block” data-draft-type=”table” data-size=”normal” data-row-style=”normal”>
| (R)-mevalonolactoneLactone form | (R)-mevalonateOpen-chain form |
Reversible hydrolysis in aqueous environments
| INCI / CAS | Mevalonolactone / 674-26-0 (EC 211-615-0) |
|---|---|
| Formula / MW | C6H10O3 / 130.14 |
| Active configuration | (R)-(–)-mevalonolactone, the naturally bioactive enantiomer |
| Regulatory identity | EU CosIng (humectant); China IECIC 2021 (No. 03342) |
Why the lactone form?
Mevalonolactone is the intramolecular δ-lactone of mevalonate; the two forms interconvert in water. The lactone is chemically stable and easier to formulate and store. Like a prodrug-like delivery form, it hydrolyzes in the aqueous environment of skin into the biologically active acid.
Isolated hepatocytes take up the lactone and channel it into sterol synthesis at least as efficiently as the free acid.
Sources: Chen B. et al., Skin Res Technol. 2022;28:804–814; Edwards P.A. et al., J Biol Chem. 1983;258:7272–7275; PubMed 901801.
1.3 One pathway supplies the lipids that maintain the barrier
- HMG-CoA reductase: the rate-limiting step; inhibited by statins.
- Mevalonate: the first committed product; can be supplied by mevalonolactone.
- Squalene → cholesterol: a structural lipid of the stratum corneum barrier.
- Coenzyme Q10: supports mitochondrial electron transport and antioxidant defense.
- Dolichol: supports protein N-glycosylation in the endoplasmic reticulum.
- Protein prenylation: anchors Ras/Rho-family signaling GTPases to membranes.
When pathway flux declines with age or stress, the supply of barrier lipids declines as well. Supporting the pathway supports the barrier.
1.4 Ceramides, cholesterol, and free fatty acids form the “mortar” of the barrier
- Ceramides: the backbone of lamellar sheets.
- Cholesterol: regulates lamellar fluidity and packing; its synthesis is required for barrier repair.
- Free fatty acids: complete the crystalline lipid matrix that limits water loss.
Of these three, cholesterol supply depends directly on the mevalonate pathway.
1.5 Blocking the pathway impairs the barrier; adding mevalonate restores it
| Condition | Observation |
|---|---|
| ControlVehicle-treated mouse epidermis | Normal lamellar body structure; barrier recovery follows the normal time course after disruption. |
| Pathway inhibitionTopical HMG-CoA reductase inhibitor | Abnormal lamellar body morphology; delayed barrier recovery. |
| Inhibition + mevalonateCo-application of mevalonate or cholesterol | Lamellar body structure normalizes and recovery is rescued. Cholesterol produces the same rescue effect. |
Epidermal cholesterol synthesis is causally required for barrier repair—and mevalonate supplementation can reverse this deficit.
Source: Feingold et al., J Clin Invest, 1990;86(5):1738–1745. Topical lovastatin model in mouse epidermis.
1.6 Cholesterol synthesis falls in aged epidermis—and mevalonate helps restore it
- Cholesterol synthesis in aged epidermis falls to about half the young level.
- Topical cholesterol only partially restores synthesis.
- Topical mevalonate restores synthesis close to the young level and improves barrier recovery.
- The effect is age-dependent: young skin is not affected.
Supplying a pathway substrate outperforms supplying the end product.
CHAPTER 02 · EVIDENCE
From cells to skin: lipid synthesis, 3D epidermal models, and a randomized human study
This chapter also includes independent technical literature on fermentation-derived (R)-mevalonolactone.
2.1 Two complementary routes in keratinocytes
- Route 1 | Substrate supply: supplies the mevalonate pathway downstream of the rate-limiting step, supporting cholesterol, isoprenoid, ceramide, and free fatty acid production.
- Route 2 | Metabolic signaling: mevalonate-derived signaling increases PPARβ/δ expression (mRNA ~1.7-fold), followed by increased ABCA12 and lamellar bodies, enabling more lipid transport and secretion into the stratum corneum.
- The effect disappears after PPARβ/δ knockdown by siRNA.
Mechanism established in cultured human keratinocytes: Chen et al., Skin Res Technol, 2022;28(6):804–814.
2.2 In vitro: free fatty acid output increases severalfold
| Control — Nile Red staining | + MVL — stronger lipid fluorescence |
| Control — Nile Red staining | + MVL — stronger lipid fluorescence |
- Free fatty acids are one of the three major structural lipids of the barrier.
- The largest increases occur in long-chain fatty acids—the same family of raw materials used to build ceramides.
- Nile Red fluorescence visually confirms the lipid increase in the same model.
This pathway does more than synthesize cholesterol—it amplifies the broader lipid-synthesis program.
Fold changes: Chen et al., Skin Res Technol, 2022. Nile Red images: independent technical literature on fermentation-derived (R)-mevalonolactone, presented at the 132nd Annual Meeting of the Pharmaceutical Society of Japan.
2.3 3D epidermal model: TEWL falls to 27% of control
- TEWL (transepidermal water loss) is a standard functional measure of barrier integrity.
- A 73% reduction in a living, stratified epidermal model goes beyond what a single-cell assay can show.
- The result connects cellular lipid data with tissue-level barrier performance.
From lipid biochemistry to a functional barrier—closed within the same model system.
2.4 Randomized human study: 0.1% MVL emulsion improves barrier and lipids
Sixty-six women in winter; randomized, vehicle-controlled; 0.1% mevalonolactone emulsion applied twice daily for 2 weeks (MVL n=30 and vehicle n=29 included in the analysis).
- Winter conditions increased TEWL; the MVL group barely increased (+1.17), while the vehicle group increased markedly (+4.91).
- Surface lipids increased in the MVL group (+3.50) and decreased with vehicle (−2.26), consistent with the in vitro lipid data.
- Stratum corneum hydration improved significantly versus vehicle (p < 0.01). Together, the three measures indicate a stronger, better-supplied barrier.
The pathway-level mechanism observed in vitro translates into measurable benefits in human skin.
2.5 Independent split-face data: (R)-MVL is associated with visible wrinkle improvement
Independent technical literature on fermentation-derived (R)-mevalonolactone (not a PuriPharm study): randomized split-face trial, 24 women, 0.05% cream, 8 weeks.
| Before use | After 8 weeks |
| Before use | After 8 weeks |
Skin surface replicas (crow’s-feet area), SV600 analysis: finer and shallower texture after 8 weeks.
Additional data from the same literature
- Water retention in a 3D epidermal model was approximately three times the control.
- TEWL decreased from approximately 4.3 to 1.2 g/m²/h (n=9).
Source: independent technical literature on fermentation-derived (R)-mevalonolactone. Not a PuriPharm study; not measured data for MEVAL 100L.
2.6 Early signals beyond the barrier
| Antioxidant network· The mevalonate pathway also builds the isoprenoid side chain of coenzyme Q10.· Patent literature proposes mevalonolactone to support epidermal CoQ10 and antioxidant defense.· Mechanistic rationale only; human data are not yet available. | Microbiome and safety· MVL inhibits Staphylococcus epidermidis biofilm formation in vitro.· Relevant to the skin and scalp surface ecosystem.· Oral-intake studies report a favorable safety profile in models. |
Directional early signals—development opportunities, not current product claims.
Sources: KR10-2018-0114391 A (melanin/tyrosinase); DE10148266 A1 (CoQ10 concept); Scopel et al., 2014, PMID 24111986; Yogev et al., PNAS, 2023;120(7):e2217831120.
2.7 Summary: one molecule, a five-step chain
| Step | Link | Meaning |
|---|---|---|
| 01 | Pathway supply | Mevalonate energizes lipid-synthesis pathways |
| 02 | Lipid output ↑ | Cholesterol, free fatty acids, ceramide precursors |
| 03 | Barrier function ↑ | TEWL falls in 3D epidermis and human skin |
| 04 | Hydration and lipids ↑ | Human RCT: hydration and surface lipids increase |
| 05 | Firmness and texture | Literature: improved elasticity and wrinkle appearance |
Healthy aging means keeping the skin’s own production line running.MEVAL 100L supports the source—not just the surface.
CHAPTER 03 · SCALP AND HAIR
The same pathway: hair follicles and epidermis share a lipid supply line
The hair follicle is one of the most metabolically active structures in the human body.
3.1 Hair follicles and epidermis rely on the same cholesterol supply
What the literature shows
- The follicular cholesterol-synthesis machinery is highly active. DHCR24, the terminal enzyme of cholesterol synthesis, is strongly expressed in hair follicles, and cholesterol is incorporated into the hair shaft during hair formation.
- The pathway is downregulated in hair loss. HMGCR and HMGCS1—genes controlling mevalonate production—are downregulated in patients with alopecia.
- Disrupting lipid signaling damages follicles. PPARγ deletion causes scarring alopecia in animal models.
- Recent research links cholesterol to hair growth. A 2025 report connects cholesterol with sympathetic-nerve activation, hair-follicle stem-cell proliferation, and hair loss when synthesis is blocked.
| ImplicationCholesterol supply in the follicle is active and essential—and compromised in hair loss. | Rational entry pointA pathway-supporting active can supply the substrate used by the tissue’s own lipid-building machinery. |
Sources: Palmer et al., 2020; Karnik et al., 2009; Nikhila et al., 2025; Guo et al., 2025. Follicle data are literature evidence, not measured results for MEVAL 100L.
3.2 Scalp care is becoming “skinified”—and the follicle is a metabolic organ
| The scalp is skin· The scalp stratum corneum uses the same lipid triad: ceramides, cholesterol, and free fatty acids.· Barrier damage appears as dryness, tightness, and flaking—the most common scalp-care concerns.· A healthy scalp barrier is the foundation for all hair benefits. | The follicle is a metabolic organ· Anagen follicles are among the most metabolically active tissues in the body.· Hair-shaft construction depends on cholesterol synthesis and lipid supply.· Pathway genes are downregulated in hair loss—supply matters. |
MEVAL 100L uses one pathway for two targets: the scalp barrier above and follicle metabolism below.
CHAPTER 04 · PURIPHARM PLATFORM
Synthetic biology turns pathway insight into a manufacturable active
High purity, the correct enantiomer, clean production, and scalability.
4.1 Producing mevalonolactone in a nature-inspired way
| Traditional chemical route | PuriPharm route — fermentation |
|---|---|
| · Petrochemical feedstocks· Multi-step synthesis relying on protecting-group chemistry· Racemic product—50% (R), 50% inactive (S)· Solvent-intensive purification· Process waste at every step | · Renewable feedstocks—sugars rather than petrochemicals· Engineered microorganisms run the full pathway in a single fermenter· Stereoselective—the biologically active (R)-enantiomer· Mild aqueous conditions—ambient temperature and pressure· Scalable—reported titers above 100 g/L in the literature |
Literature and patent data; not specifications for MEVAL 100L.
4.2 Three disciplines, one value chain
| 01 | Biology identifies the pathway. |
| 02 | Biotechnology manufactures the active. |
| 03 | Cosmetic science turns it into benefits. |
This is the PuriPharm development model behind MEVAL 100L.
4.3 Only the (R)-enantiomer enters the pathway
- Mevalonolactone has one stereocenter; the (R)-form is the natural form used by mevalonate kinase.
- The (S)-form does not enter the pathway.
- Half of a racemic mixture is an inactive “passenger.” Enantioselective fermentation removes it—every gram of MEVAL 100L is in the form skin can use.
4.4 Precision biology, cleaner chemistry
- Renewable feedstocks: sugars replace petrochemical starting materials.
- Mild aqueous fermentation: ambient temperature and pressure, without harsh reagents.
- Fewer steps, less waste: one fermenter replaces a multi-step synthesis sequence.
- A molecule biology already knows: the lactone hydrolyzes to mevalonate, a natural human metabolite.
Qualitative process attributes only; no quantitative sustainability claim is made. Life-cycle data are available upon request.
CHAPTER 05 · PRODUCT AND APPLICATIONS
MEVAL 100L: a clearly characterized molecule with nothing to hide
5.1 Product identity and recommended use level
| INCI name | Mevalonolactone |
|---|---|
| CAS / EC No. | 674-26-0 / 211-615-0 |
| Formula | C6H10O3 · MW 130.14 g/mol · water-miscible lactone |
| Stereochemistry | (R)-enantiomer—the bioactive form, produced by fermentation |
| CosIng function | Humectant (EU CosIng database) |
| IECIC 2021 (China) | Listed, No. 03342—historical maximum leave-on use level 0.05% |
| Recommended use | 0.05–1%—based on published in vitro and human studies |
Only publicly verifiable identity information is listed here; no specifications are invented. Full product specifications (appearance, purity, enantiomeric excess, microbial limits) are available from PuriPharm Co., Ltd.
5.2 One active, six skin-care directions (ranked by evidence strength)
| Direction | Evidence | Product relevance |
|---|---|---|
| 01 Barrier repair | Human RCT | Daily moisturizing and barrier creams. Supplies substrate for all three barrier lipids; TEWL benefits are validated in 3D epidermis and human skin. |
| 02 Healthy aging and firming | Technical literature | Elasticity and wrinkle-appearance care. Independent split-face data for (R)-MVL show measurable improvement within 8 weeks. |
| 03 Dry and sensitive skin | Human RCT | Winter protection and recovery. In the randomized study, hydration increased and surface lipids were preserved under winter stress. |
| 04 Tone and radiance | Exploratory | Patent data show inhibition of melanin and tyrosinase in B-16 melanocytes. A development direction, not a claim. |
| 05 Antioxidant support | Exploratory | The same pathway builds the side chain of coenzyme Q10, providing a mechanistic basis for pairing with antioxidant systems. |
| 06 Microbiome-friendly care | Exploratory | In vitro inhibition of S. epidermidis biofilm suggests relevance to the surface ecosystem. Early signal only. |
Directions 04–06 are supported only by patent-level or in vitro data; they represent development potential, not finished-product claims.
5.3 Scalp and hair: four entry points, one logic
| 01 | Scalp barrier care｜Skin evidence directly applicableLeave-on scalp tonics and serums for dry, tight, flaky scalps. The scalp stratum corneum uses the same lipid triad as facial skin—barrier evidence can be transferred directly. |
| 02 | Hair-growth support concept｜ExploratoryThe follicular cholesterol machinery is active during anagen and downregulated in hair loss. Supplying pathway substrate is a rational—but still to be validated—growth-support strategy. |
| 03 | Aging-scalp care｜Analogy to skin agingScalp skin ages like facial skin: lipid synthesis declines and the barrier weakens. The healthy-aging logic from Chapter 2 naturally extends to the scalp. |
| 04 | Microbiome-friendly scalp care｜ExploratoryIn vitro biofilm inhibition points toward scalp-ecosystem applications—an early signal to be developed, not a claim. |
Follicle-level evidence comes from pathway literature; product-level hair claims require dedicated studies. PuriPharm welcomes co-development projects.
5.4 Three skin-care concepts to start the co-development conversation
Concept A · Face | Metabolic barrier serum
0.1% MEVAL 100L combined with a ceramide–cholesterol–free fatty acid complex. Substrate plus building blocks: the serum replenishes finished lipids while feeding lipid synthesis.
Evidence anchor—human RCT: TEWL remained at +1.17 versus +4.91 with vehicle; hydration and surface lipids increased.
Concept B · Face/body | Winter repair cream
0.05–0.1% MEVAL 100L in a rich physiological-lipid base. Designed for seasonal barrier stress: dryness, tightness, and elevated TEWL in cold weather.
Evidence anchor—the randomized study was conducted in winter under real barrier stress.
Concept C · Face | Firming serum
0.05% MEVAL 100L paired with a peptide system. A metabolic view of firming: lipid supply improves skin quality while peptide signaling acts on the dermal matrix.
Evidence anchor—technical literature: elasticity R3 improved within 8 weeks (0.05% cream).
Concepts are illustrative starting points for co-development. Final claims must be validated in the finished formula; technical-literature anchors do not constitute measured data for MEVAL 100L.
5.5 Three scalp and hair concepts on the same platform
Concept A · Leave-on scalp | Scalp barrier tonic
0.05–0.1% MEVAL 100L in a lightweight water-based scalp tonic. Addresses dryness, tightness, and flaking at the source—the scalp’s own lipid supply.
Logic anchor—scalp barrier biology matches facial skin; skin RCT evidence can be transferred directly.
Concept B · Scalp serum | Anagen-support serum
0.1% MEVAL 100L in a follicle-directed leave-on serum. A metabolic concept for hair-density care: support the pathway on which anagen follicles depend.
Logic anchor—pathway genes are downregulated in hair loss (literature). Product-level validation is required.
Concept C · Scalp essence | Aging-scalp essence
0.05–0.1% MEVAL 100L paired with antioxidant ingredients. Extends the healthy-aging story to the scalp: lipid supply, barrier quality, and comfort.
Logic anchor—cholesterol data in aged skin (Haratake 2000) are relevant to scalp-skin aging.
Concepts are illustrative starting points for co-development. Hair-growth positioning is exploratory and requires dedicated product-level studies before any claim is made.
5.6 Formulating with MEVAL 100L: simple, compatible, literature-guided
| Practical guidance | Pairing logic |
|---|---|
| · Use level: 0.05–1%. Human data are concentrated at 0.05–0.1%; observe local limits (China IECIC: historical maximum leave-on use level 0.05%).· Water-miscible lactone. Can be added directly to aqueous systems and the water phase of emulsions.· Lactone ⇌ acid equilibrium. In water, MVL equilibrates with mevalonate—both are pathway-relevant; conventional skin-care pH is suitable.· Small, stable molecule. MW 130.14—no macromolecular handling constraints.· Compatible with physiological lipids. Designed to pair with ceramides, cholesterol, and fatty acids. | + Physiological lipidsSubstrate + building blocks—a complete barrier concept+ HumectantsBarrier lipid supply + water retention—a moisturization concept+ Peptides / antioxidantsMetabolic support + signaling actives—a firming concept |
General literature-guided recommendations, not a validated formula. PuriPharm technical service can provide starting formulations and stability support upon request.
CHAPTER 06 · COMMERCIAL VALUE
From science to market: the four-dimensional value framework of MEVAL 100L
| 01 | DifferentiationA new mechanism story—metabolic support for the skin’s own lipid production, not another moisturizer or occlusive. |
| 02 | EvidenceA layered evidence package: human RCT, 3D epidermis, and keratinocyte mechanism—plus clearly labeled independent literature. |
| 03 | SupplyA fermentation platform: renewable feedstocks, (R)-selectivity, and scalability—consistent quality from batch to batch. |
| 04 | ComplianceEstablished INCI identity, CosIng function, and IECIC 2021 listing—a well-documented ingredient. |
A differentiated story the marketing team can tell,and an evidence chain the regulatory team can defend.
Four market currents converge in one molecule
| Barrier-first skin care | Consumers increasingly see barrier health as the foundation of skin quality. MEVAL 100L goes directly to barrier biology—and is supported by human data. |
| Skin longevity and healthy aging | The category is shifting from anti-aging correction toward maintaining the skin’s own production capacity—exactly the metabolic story of the mevalonate pathway. |
| Skinification of scalp care | Scalp products increasingly borrow skin-care actives and language. MEVAL 100L brings scalp-relevant barrier and follicle logic. |
| Green biotech actives | Brands are replacing petrochemical synthesis with fermentation. MEVAL 100L is made by synthetic biology: renewable feedstocks, (R)-selectivity, and clean production. |
Positioning MEVAL 100L means standing at the intersection of these four currents.
Qualitative trend mapping only—no market-statistics claim is included.
Why MEVAL 100L: five reasons, one molecule
- A real mechanism—the mevalonate pathway is causally required for barrier repair.
- Human evidence—a randomized, vehicle-controlled study on real winter-stressed skin.
- The correct enantiomer—(R)-selective fermentation rather than a racemic compromise.
- Clean and scalable—synthetic-biology production based on renewable feedstocks.
- A dual platform—one active spanning skin care and scalp/hair care.
High purity · High activity · Clean production · Green biotechnology
REFERENCES AND DATA SOURCES
- Chen B, Lu N, Lee KS, Ye L, Hasegawa C, Maeda K. Application of mevalonolactone prevents deterioration of epidermal barrier function by accelerating the lamellar granule lipid transport system. Skin Res Technol. 2022;28(6):804–814. doi:10.1111/srt.13202.
- Feingold KR, Man MQ, Menon GK, Cho SS, Brown BE, Elias PM. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest. 1990;86(5):1738–1745.
- Haratake A, Ikenaga K, Katoh N, Uchiwa H, Hirano S, Yasuno H. Topical mevalonic acid stimulates de novo cholesterol synthesis and epidermal permeability barrier homeostasis in aged mice. J Invest Dermatol. 2000;114(2):247–252. doi:10.1046/j.1523-1747.2000.00875.x.
- Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta. 2014;1841(3):280–294. doi:10.1016/j.bbalip.2013.11.007.
- Edwards PA, Lan SF, Tanaka RD, Fogelman AM. Mevalonolactone inhibits the rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat hepatocytes. J Biol Chem. 1983;258(12):7272–7275.
- Scopel M, Abraham WR, Antunes AL, Henriques AT, Macedo AJ. Mevalonolactone: an inhibitor of Staphylococcus epidermidis adherence and biofilm formation. Med Chem. 2014;10(3):246–251. doi:10.2174/15734064113096660055.
- Yogev Y, Shorer Z, Koifman A, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci USA. 2023;120(7):e2217831120. doi:10.1073/pnas.2217831120.
- Palmer MA, Blakeborough L, Harries M, Haslam IS. Cholesterol homeostasis: links to hair follicle biology and hair disorders. Exp Dermatol. 2020;29(4):299–311. doi:10.1111/exd.13993.
- Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, Mirmirani P. Hair follicle stem cell-specific PPARγ deletion causes scarring alopecia. J Invest Dermatol. 2009;129(5):1243–1257.
- Panicker SP, Ganguly T, Consolo M, Price V, Mirmirani P, Honda K, Karnik P. Sterol intermediates of cholesterol biosynthesis inhibit hair growth and trigger an innate immune response in cicatricial alopecia. PLoS One. 2012;7(6):e38449. doi:10.1371/journal.pone.0038449.
- Nikhila L, Surya S, Najeeb SH, et al. Disrupted cholesterol biosynthesis and hair follicle stem cell impairment in the onset of alopecia. PLoS One. 2025;20(9):e0308455. doi:10.1371/journal.pone.0308455.
- Guo M, Jiang J, Zhang A, Yu W, Huang X. Cholesterol promotes hair growth through activating sympathetic nerves and enhancing the proliferation of hair follicle stem cells. Mol Med. 2025;31(1):86. doi:10.1186/s10020-025-01139-z.
- Yamashita M, et al. Mevalonolactone fermentation by Saccharomycopsis fibuligera. Fragrance Journal. 2000;28(2):62–65.
- Korean patent application KR10-2018-0114391 A (skin-brightening use of mevalonolactone); Korean patent KR101625898 B1 (fermentative production); German patent application DE10148266 A1 (CoQ10 support); international application WO2021041363 A1 (lipidomic effects).
- Independent technical literature on fermentation-derived (R)-mevalonolactone: split-face elasticity study (0.05% cream, 8 weeks, n=24) and Nile Red lipid data, 132nd Annual Meeting of the Pharmaceutical Society of Japan.
Data labeled as “technical literature” in this presentation were generated with fermentation-derived (R)-mevalonolactone—not MEVAL 100L—and are shown only as literature evidence.
Let’s build the next generation ofmetabolic actives together.
PuriPharm Co., Ltd.Building 6, No. 1366 Hongfeng Road, Huzhou, Zhejiang, China+86 572 2745768 · www.puriactives.com
PuriActives® MEVAL Mevalonolactone 100L — Product Presentation